Velarion · Company Intelligence
CompBrief
Fiscal year 2024

Sarah Boyce — FY2024 total compensation $14,176,480

Sarah Boyce is President and Chief Executive Officer of Atrium Therapeutics, Inc. (RNA). The company reported total compensation of $14,176,480 for fiscal year 2024.

01

Fiscal year 2024 compensation

Salary$659,900
Bonus$0
Stock awards$10,748,480
Option awards$2,157,090
Non-equity incentive plan$594,000
Pension and non-qualified deferred compensation$0
All other compensation$17,010
Total$14,176,480

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Atrium Therapeutics, Inc. filed April 29, 2025, accession 0001599901-25-000092.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2024President and Chief Executive Officer$659,900$0$10,748,480$2,157,090$594,000$0$17,010$14,176,480
FY2023President and Chief Executive Officer$634,500$0$2,766,000$7,374,840$349,000$0$15,379$11,139,719
FY2022President and Chief Executive Officer$601,400$0$0$4,319,275$430,100$0$15,336$5,366,111

Totals as disclosed in each year's own compensation disclosure for Atrium Therapeutics, Inc..

03

Peer context

Peer-group chief executive median$5,640,713
Difference from that median$8,535,767
Percentile within the disclosed peer group88th
Peers with a disclosed figure16

Medians and percentiles are computed across the peer group Atrium Therapeutics, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of Atrium Therapeutics, Inc.

Named executive officerRoleFY2024 total
Sarah Boyce this pagePresident and Chief Executive Officer$14,176,480
John MoriartyChief Legal Officer and Corporate Secretary$9,699,196
Michael MacLeanChief Financial Officer$4,941,722
W. Michael FlanaganChief Scientific Officer$4,802,896
Teresa McCarthyChief Human Resources Officer$4,622,733

The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Atrium Therapeutics, Inc. compensation brief.

05

The company page

Sarah Boyce's compensation sits inside Atrium Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Atrium Therapeutics, Inc. (RNA) compensation brief